Clinical Trials Results - National Cancer Institute

Skip to content

National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -5 of 5 Show results per page	View Search Criteria \| Help With Results


Sort By:	Version:	Format:


1.		Clinical Trial of PXD101 in Patients With Advanced Multiple Myeloma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 and over				Pharmaceutical / Industry				PXD101-301-G NCT00131261

Last Modified: 12/6/2007 First Published: 7/23/2006


2.		Phase II Study of PXD101 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or in Older Patients With Newly Diagnosed Acute Myeloid Leukemia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				NCI				CCC-PHII-68 7265, NCI-7265, CHNMC-PHII-68, NCT00357032

Last Modified: 5/23/2008 First Published: 8/13/2006


3.		Phase II Study of PXD101 as Second-Line Therapy in Patients With Unresectable Malignant Pleural Mesothelioma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Biomarker/Laboratory analysis, Treatment				Closed				18 and over				NCI				CCC-PHII-67 7255, NCI-7255, NCT00365053

Last Modified: 11/30/2007 First Published: 7/14/2006


4.		Phase I Study of PXD101 and 17-N-Allylamino-17-Demethoxygeldanamycin (17-AAG) in Patients With Metastatic or Unresectable Solid Tumors or Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Completed				18 and over				NCI				WCCC-CO-05906 7277, NCI-7277, NCT00354185


5.		Study of PXD101 Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Advanced Solid Tumors

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Closed				18 and over				Pharmaceutical / Industry				PXD101-CLN-4 NCT00413322

Select All on One Page

| | | | | | | |

A Service of the National Cancer Institute